KALA BIO (KALA) Q2 2026 earnings summary

Executive summary

• Transitioned from biologics R&D to focus on an AI platform-as-a-service model for biotech and pharma clients, leveraging legacy MSC-S assets and proprietary data.

• Discontinued KPI-012 and MSC-S platform after CHASE trial failed to meet endpoints in September 2025; now pursuing monetization or out-licensing of biologics assets and development of the Researgency AI platform.

• Actively evaluating strategic growth opportunities, including acquisitions and partnerships in AI, biotech, and related sectors.

Financial highlights

• Net loss for the three months ended June 30, 2026 was $1.6 million, a significant improvement from $11.2 million in the same quarter last year.

• Net loss for the six months ended June 30, 2026 was $3.2 million, compared to $20.1 million for the same period in 2025.

• General and administrative expenses decreased to $1.7 million for the quarter (from $4.6 million) and $3.4 million for the half-year (from $9.2 million) year-over-year.

• Research and development expenses dropped to $0.1 million for the quarter (from $6.2 million) and $0.1 million for the half-year (from $12.3 million) year-over-year.

• No grant income recognized in 2026; $0.5 million and $2.9 million recognized in Q2 and H1 2025, respectively.

Outlook and guidance

• Operating budget for the next twelve months set at $1.5–$3.2 million, focused on legal, audit, compliance, IP, and Researgency platform operations.

• Existing cash, cash equivalents, and expected loan repayments projected to fund operations through Q3 2027.

• Evaluating additional financing options, including ATM sales, private placements, and asset monetization.